GLENN LEVINE to Male
This is a "connection" page, showing publications GLENN LEVINE has written about Male.
Connection Strength
0.196
-
Erectile Dysfunction and Coronary Artery?Disease: Unfortunate Bedfellows. J Am Coll Cardiol. 2024 01 23; 83(3):427-429.
Score: 0.034
-
Meditation and Cardiovascular Health in the US. Am J Cardiol. 2020 09 15; 131:23-26.
Score: 0.027
-
Pet Ownership and Cardiovascular Health in the US General Population. Am J Cardiol. 2020 04 15; 125(8):1158-1161.
Score: 0.026
-
Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin. 2010 May-Jun; 60(3):194-201.
Score: 0.013
-
Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation. 2010 Feb 16; 121(6):833-40.
Score: 0.013
-
Degree of anticoagulation after one subcutaneous and one subsequent intravenous booster dose of enoxaparin: implications for patients with acute coronary syndromes undergoing early percutaneous coronary intervention. J Thromb Thrombolysis. 2004 Jun; 17(3):167-71.
Score: 0.009
-
Reduction of thrombus burden with eptifibatide in a patient with a non-ST segment elevation acute coronary syndrome. J Invasive Cardiol. 2000 Dec; 12 Suppl D:21D-2D.
Score: 0.007
-
Mortality differences among patients with in-hospital ST-elevation myocardial infarction. Clin Cardiol. 2020 Dec; 43(12):1555-1561.
Score: 0.007
-
Racial and Geographic Disparities in Internet Use in the United States Among Patients with Atherosclerotic Cardiovascular Disease. Am J Cardiol. 2020 11 01; 134:146-147.
Score: 0.007
-
Inferior ST-Elevation Myocardial Infarction Presenting When Urgent Primary Percutaneous Coronary Intervention Is Unavailable: Should We Adhere to Current Guidelines? Cardiovasc Drugs Ther. 2020 12; 34(6):865-870.
Score: 0.007
-
Risk Assessment of Stroke in Patients with Atrial Fibrillation: Current Shortcomings and Future Directions. Cardiovasc Drugs Ther. 2019 02; 33(1):105-117.
Score: 0.006
-
Impact of diabetes mellitus on percutaneous revascularization (CAVEAT-I). CAVEAT-I Investigators. Coronary Angioplasty Versus Excisional Atherectomy Trial. Am J Cardiol. 1997 Mar 15; 79(6):748-55.
Score: 0.005
-
Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation. 1996 Mar 15; 93(6):1107-13.
Score: 0.005
-
Early experience of a transcatheter aortic valve program at a Veterans Affairs facility. JAMA Surg. 2013 Dec; 148(12):1087-93.
Score: 0.004
-
Transcatheter aortic valve replacement as a treatment for late apicoaortic conduit obstruction in a patient with severe aortic stenosis. Circulation. 2013 Mar 19; 127(11):e491-4.
Score: 0.004
-
ACCF/SCAI/AATS/AHA/ASE/ASNC/HFSA/HRS/SCCM/SCCT/SCMR/STS 2012 appropriate use criteria for diagnostic catheterization: American College of Cardiology Foundation Appropriate Use Criteria Task Force Society for Cardiovascular Angiography and Interventions American Association for Thoracic Surgery American Heart Association, American Society of Echocardiography American Society of Nuclear Cardiology Heart Failure Society of America Heart Rhythm Society, Society of Critical Care Medicine Society of Cardiovascular Computed Tomography Society for Cardiovascular Magnetic Resonance Society of Thoracic Surgeons. Catheter Cardiovasc Interv. 2012 Sep 01; 80(3):E50-81.
Score: 0.004
-
Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: a subgroup analysis from the SYNERGY trial. Catheter Cardiovasc Interv. 2010 May 01; 75(6):928-35.
Score: 0.003
-
Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGY. Int J Cardiol. 2010 Sep 24; 144(1):36-41.
Score: 0.003
-
Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. Int J Cardiol. 2010 Mar 04; 139(2):123-33.
Score: 0.003
-
A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention. Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study. J Am Coll Cardiol. 2003 Sep 17; 42(6):1132-9.
Score: 0.002
-
Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial. J Am Coll Cardiol. 2003 Feb 05; 41(3):386-93.
Score: 0.002
-
Evaluation of a novel point-of-care enoxaparin monitor with central laboratory anti-Xa levels. Thromb Res. 2003; 112(5-6):301-6.
Score: 0.002
-
In-hospital costs of coronary stent implantation with and without eptifibatide (the ESPRIT Trial). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin. Am J Cardiol. 2002 Jan 01; 89(1):61-4.
Score: 0.002